MedPath
Found 1 clinical trials|View Analysis
Sort by:

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Drug: AC2993 7.5 mcg
Drug: Placebo 0.03 mL
Drug: Placebo 0.01 mL
Drug: Placebo 0.04 mL
Drug: AC2993 2.5 mcg
Drug: Placebo 0.02 mL
Drug: AC2993 10.0 mcg
Drug: AC2993 5.0 mcg
First Posted Date
2002-09-05
Last Posted Date
2015-02-20
Lead Sponsor
AstraZeneca
Target Recruit Count
156
Registration Number
NCT00044694
Locations
🇺🇸

Carolina Advanced Research, Cary, North Carolina, United States

🇺🇸

Fallen Timbers Internal Medicine, LLC, Maumee, Ohio, United States

🇺🇸

Utah Diabetes Center at the University of Utah, Salt Lake City, Utah, United States

and more 29 locations
© Copyright 2025. All Rights Reserved by MedPath